Top 50 Health Care Startup Investors in Oceania in December 2024

Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.

Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.

Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.

Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.

Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.

Icehouse Ventures is an early-stage venture capital firm. We exist to back the world's bravest Kiwi founders, launching global companies from New Zealand.

Blackbird is a venture capital fund based in Australia and New Zealand. We invest in every type of technology from software to space, unified by the biggest of ambitions.

Giant Leap is Australia's first venture capital fund to be 100% dedicated to investing in exceptional, rapidly scalable impact businesses.

OneVentures is one of Australia’s leading venture capital firms, with over $330M in funds under management. But they do more than invest. They take companies to that all important next stage, by actively shaping their future. They apply their years of international experience, operational and executional expertise to accelerate the growth of theirportfolio companies. A global growth focus drives their investment selection with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.

Stoic VC is an early-stage venture fund backing founders at the forefront of University Innovation. We partner with Uniseed to accelerate the commercialisation of university research across the ANZ.

AirTree is a venture capital firm investing in Australian and New Zealand technology founders from seed stage or earlier.

Connecting startup business owners with angel investors to raise capital . Access a network of expertise and investment opportunities.

Flying Fox Ventures is an early stage investment firm that invests across industry and across the micro-stages of pre-seed and seed.

We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.

Regal Funds Management was founded in 2004 by Andrew and Philip King. Regal utilises a long/short investment strategy and performs investment management and investment advisory services to a number of Australian Unit Trusts and Cayman Island Companies.

Carthona Capital is a hands-on, proactive, and thematic venture capital investor based in Sydney, Australia that invests globally.

Archangel is an early stage venture capital fund based in Australia. We work with great founders and investors to build game changing companies together.

Formed in late 2006, the Brisbane Angels Pty Ltd is a large group of private investors who actively invest in early stage technology companies, usually in South East Queensland, Australia. The members are typically active or semi-retired former senior business executives, who apart from financial input can provide much needed value adding toinvestee companies through hands-on management experience and high level business networks.

K1W1 provides startups and businesses in New Zealand with early and later-stage venture investments.

Clinton Capital Partners is a VC advisory business that specialises in raising capital and growing shareholder returns, for early stage technology companies and their investors. In addition, we invest our own funds to align company, investor and advisor. We have completed >70 successful transactions, and crystallised 14 liquidity events.Clinton Capital Partners has a long and established track record of growing companies, raising capital, conducting mergers, and creating liquidity events. When raising capital, we feel early-stage companies underestimate the time involved, the distraction to the underlying business, and the importance of identifying the “right culturally aligned” investors for their journey.

Your guide to finding and using government services.

Giving Australian founders access to the education, capital and networks needed to build significant, sustainable, global businesses of the future.

OIF is a venture capital firm focusing on partnering with entrepreneurs building businesses.

Investing in great people solving hard problems to create a better future.

EVP is an early stage venture capital firm based in Sydney Australia with c. $300M FUM across four fund vintages.Our most recent fund was launched in December 2022 and is a $100M fund. The fund targets early Series-A investments initially with cheque sizes in the range of $0.5 – $5.0 million. Our funds invest in software, are sector agnosticand have a focus on Australian based B2B SaaS companies.Over the years, we’ve backed brilliant founders building global software companies like SiteMinder, Deputy, Ignition and Shippit. We make high conviction investments, underpinned by ambition, pragmatism and a deep understanding of the software journey.

Skip Capital is a private investment fund investing in technology and infrastructure

Sydney Angels is a not-for-profit angel investment membership organisation. Since our establishment in 2008, they have stayed true to our mission of supporting the early-stage ecosystem by running processes and events that connect our investing members with promising early-stage companiesThey believe that encouraging smart investment in startupcompanies will benefit both our members’ portfolios and Australia’s emergent innovation economy.They see this as the ultimate win-win situation. Sydney Angels is led by an elected committee of ten volunteers who meet weekly. It is supported by an operations manager and alliance partners.

Investing in innovation for a healthy childhood Investing in innovation for a healthy childhood About Cure Kids Ventures Cure Kids Ventures is a seed and early stage investment fund that invests in the commercialisation of innovations in products and services with a potential to

Melbourne Angels was formed in Melbourne, Australia in early 2007. Melbourne Angels is the leading group of private investors in Victoria who actively invest in early stage and growth technology companies.The group has a strong and experienced core of members that generate deal flow, are experienced in evaluation of business propositions and actas mentors for the other members and the entrepreneurs. The members vary in age, gender, ethnicity, profession and type of experience. All members have experience of success at being entrepreneurial.This award winning group is consistently one of the most active startup investors in the country.

Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!

Starfish Ventures is an Australian venture capital firm focused on information technology, life sciences, and clean technology companies.

Founded by Steve Baxter, Transition Level Investments provides equity capital and operational expertise across Seed and Series A rounds to Australian companies. Our team focuses on a company-growth approach, adding value by assisting founders to build their expertise, expand their team, build product, scale locally and globally to position for asuccessful exit. We have a track record of identifying investment opportunities in the Australian market and helping enable global growth.

We are a community-powered VC fund making pre-seed / seed stage investments in Australian and New Zealand startups. Our community is rallied around a shared goal: to invest in the next generation of Australia and New Zealand startups at the very earliest stage, and then support them on their long a

The New Zealand Growth Capital Partners (formerly New Zealand Venture Investment Fund) was established to support early-stage technology companies and to stimulate private investment into this space.

Simplified access to top-tier managed funds and private companies

The BridgeLane Group is a privately-owned asset management firm specialising in the agricultural, real estate and innovation sectors. A significant global player in agriculture with a multi-decade record in large scale farming, the Group has a proud history in residential property development, comme

Flying Kiwi Angels ? Helping Kiwi Startups

We invest in Western Australian Innovators with bold ideas and global ambitions. We invest at Seed to Series-A in Western Australian companies.

Medical Angels is the premier medical and health-specific angel investment syndicate, comprised of over 1,000 clinicians from across Australia.

Investing in the deep science and technology that can propel humanity towards a radically better future.

QIC BioVentures, previously known as Queensland BioCapital Funds, was established by the Queensland Investment Corporation (QIC) in October 2002 as its venture capital arm specialising in biotechnology. Like any other QIC Fund, QBF's purpose is to maximize investment returns for QIC's clients. QBF does not provide grants or other formsof assistance.

Purpose Ventures is a Venture Capital Fund in Perth Western Australia backing the next generation of entrepreneurs and innovators.

Everywhere Ventures (fka "The Fund") is a first-of-its-kind early-stage venture fund created ​by founders for founders​ to support the next generation of entrepreneurs.Everywhere Ventures is a community-powered venture investing platform that integrates the capital, expertise, and mentoring of experienced founders and operators acrossten micro funds. The Fund's $50M+ under management comes almost exclusively from the over 500 founders and operators who are its limited partners. Everywhere Ventures operates from the belief that those who have actually built successful companies are best suited to advise and support early-stage startups. Everywhere Ventures invests in pre-seed deals globally usually in the first financing round the company raises. Emphasis is placed on purpose-driven teams across money, health and work verticals.

Investible is an early-stage venture capital firm backing the visionaries advancing humanity through technology in Australia, New Zealand, Southeast Asia and globally.

Venture capital and technology investments

Venture capital for high growth software companies.

The George Institute for Global Health is an independent medical research institute that helps to improve the health of millions of people worldwide. With projects in more than 50 countries, it has raised over 500 million dollars for global health research since 1999, and it has been ranked among the top 10 research institutions in the world forscientific impact by the SCImago Institution Rankings World Report in 2011, 2012, 2013, and 2014.The George Institute for Global Health’s work includes preventing heart disease in India, improving healthcare for Aboriginal and Torres Strait Islander Australians, closing healthcare gaps in China, making roads safer around the world, preventing the complications of diabetes, changing decades old thinking about intensive care, improving outcomes among stroke survivors, using mobile technology to make healthcare accessible worldwide, and developing tools to empower people to improve their own health.The George Institute for Global Health was founded in 1999 and is based in Sydney.

Join our leading Australian superannuation fund, committed to putting our members first, with a low admin fee and strong returns. Become a member today!

Right Click Capital - Australian Venture Capital Firm

GD1 is a Venture Capital firm that invests with high conviction in exciting technology companies originating from New Zealand. Our team is passionate about creating and growing global businesses, and our goal is to transform NZ made into the next generation of globally disruptive tech solutions.